[REVISION HISTORY]

CRISPR gene-editing therapy for cholesterol reduction

Updated 1 time since CLSTR started tracking revisions of this situation.

What changed

2026-09-11 13:34 UTC → 2026-09-12 05:42 UTC · added ~~removed~~

Researchers have reported successful results from clinical trials involving CRISPR-Cas9 gene-editing therapy designed to reduce cholesterol levels. Initial pilot study data involving 15 patients indicated that a single-dose infusion could lead to an approximately 50% reduction in LDL cholesterol and a substantial decrease in triglycerides. These reductions were observed to persist for more than one year without significant adverse effects. Subsequent details regarding the experimental one-time infusion therapy, known as CTX310, specify that the treatment works by delivering the CRISPR-Cas9 system to the liver to disable the ANGPTL3 gene. In the highest dosage group, LDL-C levels decreased by 52.5% and triglycerides fell by 47.8% from baseline after one year. No treatment-related serious adverse ~~events~~ effects were reported. Participants are scheduled for long-term safety monitoring for a total of 15 years in accordance with FDA recommendations. Recent trial data from both the United States and China have expanded on these findings. A study by Shanghai Jiao Tong University involving volunteers with familial hypercholesterolemia utilized a modified enzyme derived from the Hafnia paralvei bacterium to target the PCSK9 gene, resulting in a 52% reduction in LDL cholesterol over six months. Concurrently, research from the Cleveland Clinic targeting the ANGPTL3 gene corroborated previous findings, with the highest dosage group showing a 52% reduction in LDL cholesterol and a 48% reduction in triglycerides. While some participants reported mild side effects, such as fever and muscle aches, no dangerous adverse effects were observed.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.